ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Dronabinol

Also written as “Dronabinol Oral Solution”, “GW-2000-02” and “SP-104”.

Its studies are mostly in Pain · Fasting · Vomiting · Sleep Apnea, Obstructive · Cancer Pain, led by 14 companies.

Drug pageDronabinol: every studyMany companies study it; this page follows only the 20 they lead. All 183 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Oct 5, 201120 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
INSYS Therapeuticsits history only30 open or runningphase 1since Oct 5, 2011Oct 5, 2011none ahead
Jazz Pharmaceuticalsits history only30 open or runningphase 3since Apr 28, 2008Apr 28, 2008none ahead
Abbottits history only20 open or runningphase 3since Mar 21, 2008Mar 21, 2008none ahead
Scilex Pharmaceuticalsits history only20 open or runningphase 1since Jul 6, 2021Jul 6, 2021none ahead
Benuvia Therapeutics11 open or runningphase 3since Feb 11, 2026Feb 11, 2026May 30, 2028phase 3 · NCT07422311
Bionorica Researchits history only10 open or runningphase 3since Aug 13, 2009Aug 13, 2009none ahead
CannaXanits history only10 open or runningphase 1since Feb 24, 2022Feb 24, 2022none ahead
Daisy Pharma Opioid Ventureits history only10 open or runningphase 2since Nov 30, 2018Nov 30, 2018none ahead
FG Brasil LTDAits history only10 open or runningphase 3since Mar 8, 2022Mar 8, 2022none ahead
Incannex Healthcareits history only11 open or runningphase 2since Jun 3, 2026Jun 3, 2026Apr 2027phase 2 · NCT07635563

Also a collaborator on its studies: KGK Science and FGK Clinical Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Benuvia Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 11, 2026First study: phase 3 study in Aberrant Motor Behavior in DementiaFirst studyNCT07422311 · 140 planned · Australia

Ahead

  1. May 30, 2028Primary completion: phase 3 study in Aberrant Motor Behavior in DementiaNCT07422311

TargetBeta

CNR1 →read by rule
“Cannabinoid CB1 receptor agonist”ChEMBL 37, by rule

Other programs on CNR1

ProgramCompanyFurthest phaseStudies
CannabidiolruleJazz Pharmaceuticalsphase 468
RimonabantruleSanofiphase 339
CRB-913rulecorbus-pharmaceuticals-incphase 11

Studies

The one study Benuvia Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07422311Aberrant Motor Behavior in Dementia · Australia3Not yet recruitingMay 30, 2028140

How it is read

Names in the registry

  • “Dronabinol”, 4 entries
  • “Dronabinol Oral Solution”, 2 entries
  • “GW-2000-02”, 2 entries
  • “SP-104”, 2 entries
  • “IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide”, 1 entry

Codes read as this program: GW200002.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.